跳至主要内容
临床试验/NL-OMON55108
NL-OMON55108招募中不适用

PredicTive value of FluoR-18 PSMA-1007 PET/CT and anti-3-[18F] FACBC PET/CT before PLND for lymph nodE staging in primary pRostate cancer - TRACER Study

Catharina-ziekenhuis0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • 1. Biopsy proven adenocarcinoma of the prostate;
  • 2. Indication for (super)extended PLND (with or without (robot-assisted)
  • laparoscopic prostatectomy), in intermediate and high risk patients ( d*Ámico
  • score) with an MSKCC >5% lymph node prediction;
  • 3. Mentally competent and understanding of benefits and potential burden of the
  • 4. Written informed consent;
  • 5. Age >=18 years.

排除标准

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • 1. History of prior diagnosed or treated PCa.
  • 2. Known concomitant malignancies (except Basal Cell Carcinoma of the skin).
  • 3. Unwillingness or inability to undergo 18F-PSMA-1007 PET/CT and anti-3-[18F]
  • FACBC PET/CT, in combination with PLND.
  • 4. Metastasis beyond pelvic region and/or bone metastasis. Patients with bone
  • metastasis will not get a PLND, but will be included in the study for further
  • follow-up.

研究者

相似试验